Global drug company Boehringer Ingelheim Pharmaceuticals Inc., with its U.S. headquarters in Ridgefield, recently announced positive data for its new maintenance treatment ”” called Stiolto Respimat ”” for chronic obstructive pulmonary disorder.
Stiolto Respimat was approved for use in the U.S. in May for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or acute deterioration of COPD, Boehringer Ingelheim said in announcing the results.
The data were presented at the European Respiratory Society International Congress, Sept. 26 to Sept. 30, in Amsterdam.
“As a leader in COPD care for more than 40 years in the U.S., we”™re encouraged by these new data that further our knowledge of the potential benefits of Stiolto Respimat,” Dr. Danny McBryan, vice president for clinical development and medical affairs/respiratory for Boehringer Ingelheim, said. “Based on the available clinical data, we believe Stiolto Respimat will help address unmet patient needs in the COPD community.”
